Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07513324 · ClinicalTrials.gov registry record · Phase 2
Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT07513324 is a Phase 2 study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 116 participants.
The verdict
NCT07513324, a Phase 2 study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The purpose of this study is to assess risk for HPV driven oropharyngeal cancers by using HPV blood tests and clinical features (such as tumor stage and smoking status) to determine appropriate treatment to improve survival outcomes in participants with stage I, II, or III, HPV-associated oropharyngeal (tongue base or tonsil) squamous cell carcinoma,.
Interventions
- OTHER Observation
- DRUG Pembroluzimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2030-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07513324
The ClinicalTrials.gov registry entry for NCT07513324 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Observation is the first listed.
NCT07513324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07513324 about?
NCT07513324 is a clinical study titled "Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)". The purpose of this study is to assess risk for HPV driven oropharyngeal cancers by using HPV blood tests and clinical features (such as tumor stage and smoking status) to determine appropriate treatment to improve survival outcomes in participants with stage I, II, or III, HPV-associated oropharyng...
What is the current status of trial NCT07513324?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2026-07-01. Estimated completion is 2030-01-01.
What interventions are being tested in trial NCT07513324?
The interventions under investigation include: Observation (OTHER), Pembroluzimab (DRUG).
Who is sponsoring clinical trial NCT07513324?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.